{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Kobayashi S"],"funding":["the Kanagawa Prefectural Cancer foundation"],"pubmed_abstract":["<h4>Background</h4>Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is often used as a subsequent treatment, although its efficacy and safety are yet to be fully elucidated. We aimed to evaluate the efficacy and safety of FOLFOX as a third- or later-line treatment for patients with advanced pancreatic ductal adenocarcinoma.<h4>Methods</h4>We conducted a single-centre, retrospective study that enrolled 43 patients who received FOLFOX after failure of gemcitabine-based regimen followed by 5FU/LV + nal-IRI therapy between October 2020 and January 2022. FOLFOX therapy consisted of oxaliplatin (85 mg/m<sup>2</sup>), levo-l"],"journal":["BMC cancer"],"pagination":["177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9945590"],"repository":["biostudies-literature"],"pubmed_title":["FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study."],"pmcid":["PMC9945590"],"pubmed_authors":["Ueno M","Yamachika Y","Nagashima S","Tsunoda S","Furuse J","Maeda S","Kobayashi S","Morimoto M","Tozuka Y","Tezuka S","Fukushima T"],"additional_accession":[]},"is_claimable":false,"name":"FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.","description":"<h4>Background</h4>Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is often used as a subsequent treatment, although its efficacy and safety are yet to be fully elucidated. We aimed to evaluate the efficacy and safety of FOLFOX as a third- or later-line treatment for patients with advanced pancreatic ductal adenocarcinoma.<h4>Methods</h4>We conducted a single-centre, retrospective study that enrolled 43 patients who received FOLFOX after failure of gemcitabine-based regimen followed by 5FU/LV + nal-IRI therapy between October 2020 and January 2022. FOLFOX therapy consisted of oxaliplatin (85 mg/m<sup>2</sup>), levo-l","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-19T00:55:23.529Z","creation":"2025-02-19T03:59:46.954Z"},"accession":"S-EPMC9945590","cross_references":{"pubmed":["36809997"],"doi":["10.1186/s12885-023-10654-3"]}}